Publications

Wood M, Mease K, Lueth J. Study monitoring: Expert approaches for a successful nonclinical program. Exhibitor-Hosted Session, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Jackson JW, Frederick C Streich Jr, Pal A, Coricor G, Boston C, …, Wood M, et al. 2024. An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis. Sci Signal 17(844):eadn6052; doi: 10.1126/scisignal.adn6052. PMID: 38980922.

Mihalchik A, Wood M. Considerations for standardization and derivation of pediatric and neonatal tolerable exposure limits for extractable and leachable compounds from medical devices. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

Fryzek J, Bylsma L, Mease K, Movva N, Welsh BT, Wood M. 2020. Critical insights into nonclinical toxicology and real-world evidence essential for a successful rare disease product launch. EpidStrategies, Inc. White Paper.

Kimzey AL, Piche M-S, Wood M, Weir AB, Lansita J. 2018. 11.19 – Immunophenotyping in drug development. In: Comprehensive Toxicology, 3^rd Ed. Vol 11:399–427.